Introduction This is one of five questionnaires that Member States are invited to complete ahead of the 40th WHO Expert Committee on Drug Dependence. This questionnaire will ask you about cannabis plant and cannabis resin. Definition: The dried flower/ leaf of the cannabis sativa plant Examples: marijuana, weed, pot, hashish, and kief -------------------------------------------------------------------------------------------------- The questionnaire will take about 15-25 minutes to complete. You may return to the questionnaire to amend your responses at any time until the closure of the questionnaire. To commence the questionnaire, you will first be asked to indicate that you agree to WHO data sharing policy. The responses of this questionnaire will be compiled into a report that will be publicly available on the WHO ECDD website. The name of your country may be presented alongside questionnaire data unless you indicate that you wish for your country name to be anonymised in the final report. If you wish to submit any information to the attention of the ECDD Secretariat, you will be invited to upload documents at the end of the questionnaire. We thank you in advance for taking the time to complete this questionnaire.
General Information * 1. Focal point contact details Name * 2. Please indicate your country
WHO Data Sharing Policy Statement of policy on data sharing Data are the basis for all sound public health actions and the benefits of data sharing are widely recognized, including scientific and public health benefits. Whenever possible, WHO wishes to promote the sharing of health data, including but not restricted to surveillance and epidemiological data. In this connection, and without prejudice to information sharing and publication pursuant to legally binding instruments, by providing data to WHO, the [Ministry of Health][other responsible governmental entity] of [Country]: Confirms that all data to be supplied to WHO (including but not limited to the types listed in Annex 3) hereunder have been collected in accordance with applicable national laws, including data protection laws aimed at protecting the confidentiality of identifiable persons; Agrees that WHO shall be entitled, subject always to measures to ensure the ethical and secure use of the data, and subject always to an appropriate acknowledgement of [Country]: - to publish the data, stripped of any personal identifiers (such data without personal identifiers being hereinafter referred to as the Data ) and make the Data available to any interested party on request (to the extent they have not, or not yet, been published by WHO) on terms that allow noncommercial, not-for-profit use of the Data for public health purposes (provided always that publication of the Data shall remain under the control of WHO); - to use, compile, aggregate, evaluate and analyse the Data and publish and disseminate the results thereof in conjunction with WHO s work and in accordance with the Organization s policies and practices. Except where data sharing and publication is required under legally binding instruments (IHR, WHO Nomenclature Regulations 1967, etc.), the [Ministry of Health][other responsible governmental entity] of [Country] may in respect of certain data opt out of (any part of) the above, by notifying WHO thereof in writing at the following address, provided that any such notification shall clearly identify the data in question and clearly indicate the scope of the opt-out (in reference to the above), and provided that specific reasons shall be given for the opt out. ecddsecretariat@who.int
* 3. Please confirm that you agree I agree for the information provided in this questionnaire to be published in a report
General cannabis information * 4. Do you have any information about the use of cannabis plant/cannabis resin for any purpose (including medical or non-medical use) in your country? Yes No - you will be directed to the end of the questionnaire
Medical use of cannabis plant /resin This page will ask you about approved medical use of cannabis plant and resin only. Cannabis plant and cannabis resin includes the dried flower/ leaf of the cannabis plant. It also includes hashish and kief. * 5. At national level, is cannabis plant or resin legally approved for medical use in your country? Yes No Other (please specify)
Medical use: Therapeutic indications 6. Please indicate any approved therapeutic indications for the use of cannabis plant/resin in your country Epilepsy Multiple sclerosis, amyotrophic lateral sclerosis, spinal cord injury Arthritis Dystonia Huntington s disease Parkinson s disease Tourette s syndrome Glaucoma Anxiety Depression PTSD Schizophrenia /psychosis Alzheimer s disease/ dementia Skin disease Irritable bowel syndrome Inflammatory bowel disease Liver disease Obesity/ diabetes Cancer HIV/AIDS Chronic pain Crohn's disease Attention Deficit Disorder (ADD) None specified Other (please specify)
7. Please indicate any symptoms that cannabis plant/resin is approved to treat Acute pain Chronic non-cancer pain Cancer pain Nausea/ vomiting Appetite stimulant Headaches/ migraines Muscle spasms Seizures Sleep problems Alcohol withdrawal symptoms Opioid withdrawal symptoms Palliative care Other (please specify) 8. Please indicate whether there are any permitted marketed products of cannabis plant and cannabis resin. Name of marketed product & CBD /THC content (if known): Name of marketed product & CBD /THC content (if known): Name of marketed product & CBD /THC content (if known): Name of marketed product & CBD /THC content (if known): Name of marketed product & CBD /THC content (if known):
9. Are there any ongoing approved clinical trials in your country that are developing cannabis plant/resin for medical use? Yes No Other (please specify) 10. Please indicate product name/ trial number/ study phase of any ongoing trials that are developing products of cannabis plant/ resin for medical use Product name Product name Product name Product name Product name Product name
Medical use: Access 11. Do individuals require a prescription to obtain medical cannabis plant or resin? Yes No N/A Other (please specify) 12. What types of professionals are allowed to prescribe cannabis plant and cannabis resin? Medical doctor / psychiatrist Osteopath Nurse/nurse prescriber Pharmacist Psychologist Physiotherapist Healthcare worker No prescription is required Other (please specify)
13. What kinds of settings are approved to legally dispense cannabis plant/resin in your country? At a doctor's office Pharmacies Online Retail shops Licensed/specialised cannabis dispensaries Hospitals Outpatient clinics Palliative care facilities Nursing homes Other (please specify) 14. If patients use medical cannabis plant/resin on prescription or recommendation of a health professional, will they be reimbursed for the costs of their medication? Yes, they will be reimbursed by National Health Services Yes, each health insurance company in the country will reimburse the patients Some health insurances do reimburse for the costs, others do not Patients have to make extra health insurance arrangements to be reimbursed No, patients cannot be reimbursed Other (please specify) 15. Are any clinical guidelines used in your country for the prescribing of medical cannabis plant/resin? No N/A Yes (please specify)
16. Is there a regulatory agency in your country that monitors cannabis plant/ cannabis resin for medical use? No N/A Yes (please specify) 17. How would you describe the trend in the number of users of cannabis plant/cannabis resin for medical use over the last 3 years? The number has The number has The number has The number has substantially slightly remained the The number has substantially Don't know/ increased increased same slightly reduced reduced unsure Cannabis plant Cannabis resin
Medical use: National legislation This section will ask about the general policies in your country towards cannabis-related substances for medical use 18. In the past 3 years, has your country changed its national legislation around access to cannabisrelated substances for medical use? Yes, my country has changed its legislation No, my country has not changed its legislation Cannabis plant/ cannabis resin Unknown/ Other (please specify) 19. If yes, what types of legislative changes has your country made for medical use of cannabis plant/ resin? Change to the legal status of medical cannabis Changes to the supply of medical cannabis (e.g. changes in licensing, import or export of products) Changes to access to medical cannabis (e.g. variety in products, therapeutic indications etc) Other (please specify) 20. Is your country currently considering changes to its national legislation around access to cannabis and cannabis-related substances for medical use? Yes, my country is preparing changes in its legislation No, my country is not preparing changes in its legislation Cannabis plant and cannabis resin Unknown/ Other (please specify)
21. In your opinion, how do you feel the changed legislation around access to cannabis plant/resin for medical use would impact / has impacted public health in your country? There would There would be /has be /has been a There would There would be/ has been a slightly There would be/ has been a been a substantially negative negative be/ has been slightly positive substantially positive impact on public impact on no impact on impact on impact on public Don't know/ health public health public health public health health unsure Increased availability for medical use Decreased availability for medical use Please explain your response:
Non-medical use of cannabis plant and cannabis resin The next section will ask you about non-medical use of cannabis plant and resin in your country. Non-medical use includes both recreational use, and use for self-medication purposes. * 22. On a national level, is cannabis plant (or cannabis resin) legally available for non-medical use in your country? Yes No Other (please specify) 23. Is cannabis plant/ cannabis resin used for cultural, ceremonial, or religious purposes in your country? No Unknown Yes (please specify) 24. Does your country collect prevalence data around the use of cannabis plant / cannabis resin? Yes No N/A Unknown
Prevalence of non-medical cannabis use 25. Prevalence of use of cannabis plant/ resin amongst adults ( over 18 years of age) Number (or % of population) used in lifetime Number (or % of population) used in the last year Number (or % of population) used in the past month Year of survey data Prevalence by age group (if known) 26. Prevalence of use of cannabis plant/ resin for non-medical use amongst young people ( below 18 years of age) Number (or % of population) used in lifetime Number (or % of population) used in the last year Number (or % of population) used in the past month Year of survey data Prevalence data by age group (if available)
27. How would you describe the number of users cannabis plant/cannabis resin for non-medical use over the last 3 years in your country? There has been a There has been a There has been a There has been a significant increase slight increase in There has been no slight decrease in significant decrease in use use change in use use in use Non-medical use by adults Non-medical use by young people (below age 18) Comments:
Public health impact of use: Primary Care 28. Does your country collect data about presentations to primary care settings due to the use of cannabis plant/resin? Yes No Unsure
Primary Care II 29. Number of primary care presentations relating to cannabis plant/resin Number of presentations relating to substance alone Number of presentations relating to substance in combination with other substances Year of data collection 30. Does your country collect data about presentations to emergency care settings due to the use of cannabis plant/resin? Yes No Unsure
Public health: Emergency settings 31. Number of individuals in the past year presenting to emergency settings relating to the use of cannabis plant/resin Relating to substance alone: Relating to substance with other substances: Year of data collection 32. Please list the adverse effects presented for cannabis plant/resin at the emergency room/department Injuries related to impaired driving Injuries related to accidents/falls Prenatal exposure Cannabis use disorders / withdrawal Psychiatric comorbidity Respiratory problems 33. Does your country collect data about presentations to substance misuse treatment settings due to the use of cannabis plant/resin? Yes No Unsure
Public health: Substance misuse treatment 34. Number of individuals in the past year presenting to substance misuse treatment due to cannabis plant/resin Relating to substance alone Relating to substance and other substances Year of data collection 35. Does your country collect data about calls to poison centres due to the use of cannabis plant/resin? Yes No Unsure
Public health impact: Poison control centres 36. Number of calls to poison control centres due to the use of cannabis plant/ resin Relating to substance alone Relating to substance and other substances: Year of data collection 37. Does your country collect data about cases of impaired driving due to the use of cannabis plant/ resin? Yes No Unsure
Public health impact: Impaired driving 38. Number of cases of impaired driving due to cannabis plant/ resin Relating to cannabis alone Relating to cannabis and other substances
Non-Medical Use: National legislation This section will ask you about your national policies on the non-medical use of cannabis 39. In the past 3 years, has your country changed its national legislation around access to cannabis plant/resin for non-medical use? Yes, my country has changed its legislation No, my country has not changed its legislation Cannabis plant/ cannabis resin Please explain your response: 40. If yes, what types of legislative changes has your country made for non-medical use of cannabis plant/ resin? 41. Is your country currently considering changes to its national legislation around access to cannabis plant/resin for non-medical use? Yes, my country is preparing changes in its legislation No, my country is not preparing changes in its legislation Cannabis plant and cannabis resin Please explain your response:
42. In your opinion, how do you feel the changed legislation around access to cannabis plant or cannabis resin for non-medical use would impact / has already impacted public health in your country? There would be/ There would be/ There would be/ There would be/ has been a has been a There would be/ has been a has been a significantly slightly negative has been no slightly positive significantly negative impact impact on public impact on public impact on public positive impact Don't know/ on public health health health health on public health unsure Increased availability for non-medical use Decreased availability for non-medical use Please explain your response:
Additional comments / information In this section, you may provide any additional information that you wish for the WHO Expert Committee to consider. You can provide comments on cannabis substances for medical nonmedical and medical use. You may also wish to upload data or documents for the committee to consider. This may include results of national surveys. For the transmission of sensitive or highly confidential information, please submit these documents directly to the ECDD at ecddsecretariat@who.int 43. Comments 44. File upload Choose File No file chosen 45. File upload Choose File No file chosen 46. File upload Choose File No file chosen